Approval · Notice of Compliance 31395 · 2023
SARCLISA: Notice of Compliance 31395
Issued August 10, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31395
- Date
- August 10, 2023
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternate drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SARCLISA | Not yet assigned | — |
Medicinal ingredients
- ISATUXIMAB 100 MG per 5ML
- ISATUXIMAB 500 MG per 25ML